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Introduction 
 
Lymphangioleiomyomatosis (LAM) is an orphan lung disease, which occurs sporadically or in 
association with the genetic disease tuberous sclerosis complex (TSC)[1, 2]. Sporadic LAM is 
rare, affecting approximately 1:400,000 adult women; whereas in TSC, LAM occurs in 30-40% 
of adult women[3, 4] and exceptionally in men and children[5, 6].   
Although some are asymptomatic, patients with LAM usually develop progressive dyspnoea, 
recurrent pneumothorax, chylous collections and occasionally haemoptysis[1]. Extrapulmonary 
complications of LAM include lymphadenopathy and cystic masses of the axial lymphatics 
termed lymphangioleiomyomas which may result in abdominal and pelvic lymphatic 
obstruction[7]. LAM is often associated with angiomyolipoma, a benign tumour generally 
occurring in the kidneys[8], and an increased frequency of meningioma[9]. LAM is highly 
variable in terms of clinical features and rate of progression: this together with an absence of 
clear prognostic factors results in patients being given conflicting information about their 
prognosis. 
Diagnosis is made by tissue biopsy and/or a combination of history and computed tomography 
(CT) scanning. Tissue biopsy is generally from the lung, especially when surgical procedures for 
the treatment of pneumothorax are required but occasionally lymph nodes or 
lymphangioleiomyomas are sampled. Pathological diagnosis is reliant on characteristic LAM cell 
morphology and positive immunoreactivity to smooth muscle actin and HMB-45 antibodies. 
Increasingly high resolution CT scanning (HRCT) is used to diagnose LAM without resorting to 
lung biopsy; however a number of conditions with multiple pulmonary cysts can mimic LAM 
and the reliability of this approach has not been studied.  
As LAM is rare, there have been no controlled trials of its management which varies from centre 
to centre. Supportive treatment includes management of airflow obstruction and hypoxaemia with 
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bronchodilators and oxygen respectively, specific treatment for surgical or pleural complications 
including pneumo- and chylothorax, and interventional treatment of renal lesions[10, 11]. As 
LAM is a disease of women and is thought to be accelerated by oestrogen: oophorectomy, 
tamoxifen, progesterone and gonadotropin-releasing hormone (GnRH) analogues have been used 
although there is no evidence that any are effective. More recently the finding of abnormalities in 
the TSC1/2 genes resulting in constitutive activation of the kinase mammalian target of 
rapamycin (mTOR)[12, 13] has led to trials of mTOR inhibitors including sirolimus in patients 
with LAM and angiomyolipoma[14, 15].  
The purpose of the LAM Task Force was to produce evidence based, consensus guidelines for the 
diagnosis, assessment, and treatment of patients with LAM. 
 
METHODS 
 
The two Chairmen (S. Johnson and J.F. Cordier) designed the objectives of the LAM Taskforce, 
submitted the project to the European Respiratory Society for sponsorship, contacted recognised 
specialists with competence in LAM to participate in the Core and Consultant panels, and 
organised the process of elaborating guidelines through face to face meetings and electronic 
communication. 
The working party was composed of three panels. The Core panel had overall responsibility for 
the guidelines and developing the project. The Consultant panel advised on specialist aspects of 
the guidelines including lung transplantation, pathology, and tuberous sclerosis. The Review 
panel reviewed the documents and comprised all members of the Core and consultant panels plus 
international experts in LAM, interstitial lung diseases, and representatives of European Thoracic 
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Societies.  
The process of guideline development was as follows: 1) question formulation, 2) evidence 
collection and synthesis (Core and Consultant panels), 3) grading of recommendation strength 
using the 2004 American College of Chest Physicians health and science policy grading 
system[16] (Core and Consultant panels), 4) circulation of documents and first version of the 
guidelines (Core and Consultant panels), 5) first formal review with scoring of agreement and 
proposals for modifications using Likert scale statistics and definitions[17] (Core, Consultant and 
Review panels), 6) integration of proposals (Core panel), 7) second formal review with re-
assessment of agreement (Core, Consultant and Review panels), and 8) final revision (Core 
panel). Final recommendations are scored by 1) strength of recommendation: (grade) from A 
(strongest) to D (weakest) and I (inconclusive), 2) quality of evidence (quality) 3), magnitude of 
benefit, and 4) strength of expert consensus. Further details are contained in appendix 1. 
 
DESCRIPTION OF DISEASE 
Respiratory manifestations 
Symptoms In most cases of LAM respiratory manifestations dominate the clinical picture. 
Dyspnoea is the most common symptom occurring in almost all patients and is the presenting 
feature in 42% of cases (Table 1). In many cases dyspnoea is associated with wheeze and cough 
and may be caused by replacement of the lung parenchyma by cysts, by airflow obstruction, and 
by the presence of pneumothorax or chylous pleural effusions. Cough is generally dry in the early 
stages of LAM although patients with more advanced disease may produce sputum and have 
recurrent infections. A small number of patients have intermittent, mild, haemoptysis and others 
cough sticky white secretions, which probably represent chyloptysis. Pneumothorax appears the 
most common mode of presentation and is bilateral in up to 4% of patients[18]. Pneumothorax is 
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more common during pregnancy[10] and pneumothorax during pregnancy should raise the 
possibility of LAM.  
 
 At presentation  During course of disease 
Pneumothorax  43 (256)  65 (213) 
Dyspnoea  42 (256)  87 (164) 
Cough  20 (221)  51 (164) 
Haemoptysis  14 (138)  22 (164) 
Phlegm  27 (230) 
Chyloptysis  7   (230) 
Chylothorax  12 (256)  28 (213) 
Table 1. Summary of symptom prevalence expressed as percentage (n) from 10 surveys [3, 7, 8, 
10, 19-24]. 
 
Physical findings There are generally no positive physical findings in patients with early disease 
unless pneumothorax or chylous effusion is the presenting problem. In those with more advanced 
disease, signs of lung hyperinflation, wheezing and cyanosis may be present. Signs of TSC 
(appendix 2) may be present in those with TSC-LAM.  
Physiological tests Patients with LAM develop airflow obstruction and impaired gas transfer 
with preserved lung volumes. Early studies featured patient cohorts who had more advanced 
disease and the majority of these patients had abnormal spirometry and gas transfer[20, 25]. More 
recent studies using national cohorts have included more patients with mild or early disease (table 
2). In two such studies, TLCO was within the normal range in 18% of 80 patients whereas FEV1 
was normal in 42% of 45 patients[3, 8]. Lung function, particularly TLCO and FEV1 have been 
correlated with histological[26] and CT grading of disease severity[27] and used to assess disease 
progression in large series of patients. Patients with LAM have limitation of their exercise 
performance. Cardiopulmonary exercise testing has shown that maximal oxygen uptake during 
exercise (VO2max) correlated well with TLCO, extent of disease on CT[28] and was more 
sensitive at detecting early disease than standard lung function[28].  
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Series Number 
in series 
FEV1 FVC TLC RV TLCO 
Lazor[29] 31 72 85 97 119 55 
Ryu[24] 218 70 87 96 103 67 
Taveira DaSilva[30] 275 75 87 94 104 73 
Johnson[10] 47 65 82 98  62 
Table 2. Baseline lung function in recent series of LAM (% predicted values).  
 
 
Radiological findings The chest radiograph may be normal in early disease although in the 
majority of cases cysts, bullae, reticulonodular shadows and hyperinflation are present with 
pneumothorax and pleural effusion also seen (table 3). Multiple, round, thin-walled, well-defined 
air-filled cysts with preserved or increased lung volume are seen in all patients with LAM 
examined by HRCT (figure 1a).  
 
 At presentation During course of disease 
Chest X-ray   
Normal 5  (147) 0 (32) 
Reticulonodular change 68 (147) 94 (32) 
Cysts/bullae 47 (147) 41 (32) 
Pleural effusion 5  (78) 28 (32) 
Pneumothorax 35 (78) 81 (32) 
Hyperinflation 27 (147) 25 (32) 
HRCT   
Cysts 100 (104) 100 (35) 
Ground glass opacity 29  (104)  
Nodules 9    (104)  
Pneumothorax 16 (38) 6 (35) 
Pleural effusion  13 (38) 14 (35) 
Hilar / mediastinal adenopathy 6 (104)  
Dilated thoracic duct  11 (35) 
Pericardial effusion  6 (35) 
Table 3. Frequency of radiological findings in LAM expressed as percentage (n).Adapted from 
references [3, 8, 20, 25] 
 
     
 9 
Figure 1.  
(a) HRCT scan showing typical changes in a 
patient with moderate LAM. (b) CT of an 
asymptomatic renal angiomyolipoma 
showing characteristic heterogeneous lesion 
in the left kidney (arrow). Further lung, renal 
and abdominal CT images are shown in 
supplementary figure 2. 
 
 
 
 
 
 
 
 
 
 
Lymphatic manifestations 
The axial lymphatics of the thorax, retroperitoneum, abdomen, and pelvis may become thickened, 
dilated and in some cases occluded by LAM cells[19, 31]. This results in lymphadenopathy in 
40% of patients[7] and enlarged cystic lymphatic collections termed lymphangioleiomyomas in 
21% of patients[7, 32]. Symptoms are rare in patients with abdomino-pelvic lymphadenopathy. 
45% of those with lymphangioleiomyomas develop symptoms including palpable masses, 
abdominal discomfort, bloating, leg oedema, paresthaesia and local pressure symptoms, 
particularly where pelvic masses compress the bladder[32, 33]. Rupture of 
lymphangioleiomyoma has been occasionally reported, leading to chylous ascites in 10%[34], 
a
b
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chyluria, abdominal discomfort, distension and bloating. Chylous pericardial effusions have been 
occasionally described although are rarely clinically significant. In addition approximately 7% of 
patients develop chyloptysis, presumably due to occlusion of lung parenchymal lymphatics[24]. 
Chyluria, occurring by a similar mechanism in the bladder has also been observed[35].  
 
Renal manifestations  
Angiomyolipomas are benign tumours consisting of smooth muscle (LAM) cells, blood vessels 
and fat (figure 1b). Angiomyolipomas occur in up to 50% of patients with sporadic LAM, 69-
80% of patients with TSC[36-39] and almost all patients with TSC-LAM[40]. The majority of 
angiomyolipomas are less than 1.5 cm but in some patients, especially those with TSC, 
angiomyolipomas may enlarge and multiple tumours can occur in both kidneys[41]. Tumours 
greater than 4 cm, particularly those with aneurysmal vessels are prone to bleeding, presenting as 
haematuria and haemoperitoneum. During the course of the disease further angiomyolipomas 
may develop or enlarge. TSC is associated with other renal lesions including renal cysts and 
polycystic kidney disease that may result in chronic renal failure[22, 38, 39, 42-46].  
 
Meningioma 
Both sporadic and TSC-LAM are associated with an increased risk of meningioma. Meningioma 
has been reported in case reports[47-49] and in a study of 250 patients was detected by screening 
in 9 patients (3.6%), three of whom were symptomatic[9, 50].  
 
TSC-LAM 
The recent observations that 26-39% of adult women with TSC have lung cysts consistent with 
LAM[2, 51, 52] but less than 3% have symptoms of LAM[53] suggests that a large number of 
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women with TSC have a mild form of the disease which may progress only slowly or not at all. 
Consistent with this, those with sporadic LAM in the National Heart Lung and Blood Institute 
(NHLBI) registry, had more cysts and worse lung function than those with TSC-LAM[24, 54]. 
However, this observation is prone to ascertainment bias, with TSC patients more likely to be 
diagnosed with LAM than the general population. Although TSC-LAM can be asymptomatic it 
may be as severe as the sporadic form in some cases. It is important to consider TSC in those 
with LAM. TSC has a highly variable phenotype with only one third of patients having the 
classical triad of epilepsy, learning difficulties, and facial angiofibromas. Those who do not have 
epilepsy or learning difficulties may have mild cutaneous features of TSC which can be 
overlooked. In many cases a history of childhood epilepsy, renal disease, skin problems, learning 
difficulties or a family history of these problems may be found although 2/3 of cases of TSC arise 
as spontaneous mutations where no family history is present. Diagnostic criteria for TSC are 
found in appendix 2[55].  
 
Pathology 
The lung parenchyma is progressively replaced by a combination of cysts and a nodular 
proliferation of immature smooth muscle and perivascular epithelioid cells, called LAM cells[56-
58] (figure 2). LAM cell proliferations are usually found around lymphatic vessels, beneath the 
pleura, and the alveolar septa. LAM nodules are heterogeneous proliferations of spindle and 
epithelioid LAM cells associated with proliferation of lymphatics[59]. LAM cells, particularly 
epithelioid cells, express pre-melanocyte proteins which can be detected immunohistochemically 
by the antibody HMB-45. This combination of melanocytic and smooth muscle origin is 
consistent with the perivascular epithelioid cell origin for LAM cells[60, 61]. Sporadic and TSC-
LAM is morphologically indistinguishable. LAM cells frequently infiltrate the axial lymphatics 
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and the thoracic duct can also be involved. Rarely other organs such as the serosa of the uterus or 
fallopian tubes can be involved.  
 
 
 
 
 
 
 
Figure 2. 
Lung biopsies showing proliferating nodules of LAM cells at low (left) and high (right) power 
stained with haematoxylin and eosin. Further pathological images are shown in supplementary 
figure 3. 
 
At a molecular level LAM cells are characterised by dysregulation of the mTOR pathway as the 
result of mutations in the TSC1/2 genes[12, 62, 63]. This leads to a complex cell phenotype 
capable of increased growth, metastatic behaviour, and the expression of hormone receptors, 
proteases, and growth factors including vascular endothelial growth factor (VEGF)[64]. This is 
discussed further in appendix 3. 
 
PROPOSED DEFINITIONS AND DIAGNOSTIC WORKUP FOR LAM 
 
Diagnostic criteria  
No studies have been performed which examine the diagnostic accuracy of strategies which do 
not include lung biopsy (the gold standard for diagnosis in most studies). The diagnostic criteria 
result from approaches used by large series, registries[3, 24, 25, 30, 65] and expert opinion. 
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DEFINITE LAM 
1. Characteristica or compatiblea lung HRCT 
and 
lung biopsy fitting the pathological criteria for LAMa 
  OR 
2. Characteristica lung HRCT and any of the following:  
- angiomyolipoma (kidney)b 
- thoracic or abdominal chylous effusionc 
- lymphangioleiomyomad or lymph-node involved by LAMd 
- definite or probable TSCe 
PROBABLE LAM 
1. Characteristica HRCT and compatible clinical historyf 
OR 
2. Compatiblea HRCT and any of the following: 
- angiomyolipoma (kidney)b 
- thoracic or abdominal chylous effusionc 
POSSIBLE LAM 
 Characteristica or compatiblea HRCT 
 
FOOTNOTES 
a. as defined below 
b. diagnosed by characteristic CT features and/or on pathological examination  
c. based on visual and/or biochemical characteristics of the effusion 
d. based on pathological examination 
e. see appendix 2  
f. compatible clinical features include pneumothorax (especially multiple and/or bilateral) and/or 
altered lung function tests as in LAM 
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REMARKS 
1. LAM is considered associated with TSC (TSC-LAM) when definite or probable TSC is 
present. Otherwise LAM is considered sporadic. 
2. The diagnosis of LAM defined above is only for female patients. LAM is most 
exceptional in males without TSC (definite or probable) and exceptional in males with 
TSC. In these, diagnosis requires characteristic or compatible HRCT and typical 
pathological features on lung biopsy. 
3. The diagnosis of LAM requires exclusion of the alternative causes of cystic lung disease 
(section 5.3). A complete diagnostic work-up for these alternative causes of cystic lung 
disease is necessary in patients with probable and especially possible LAM. 
Agreement on diagnostic criteria (Consensus) very good 
 
Pathologic criteria for diagnosis  
Two lesions characterize LAM: cysts and a multifocal nodular proliferation of immature smooth 
muscle and perivascular epithelioid cells (LAM cells)[56-58]. Both lesions are found together in 
variable percentages and the findings may be inconspicuous in early disease. Epithelioid and 
immature looking smooth muscle cells form the nodular lesions characteristic of LAM. A few 
cells, but also aggregates of more than 20 cells can form the nodules. While perivascular 
epithelioid cell and spindle cells are present in LAM, intermediate forms with a combined 
muscular and epithelioid phenotype can be encountered. Thus it seems appropriate to consider 
them as a morpho-phenotypical modulation of the same cell, probably arising from a common 
precursor[66, 67]. Sporadic and TSC-associated LAM are morphologically and phenotypically 
indistinguishable.  
The sensitivity and specificity of the pathologic changes seen in LAM have not been determined. 
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As a consequence the correct diagnosis mainly relies on the experience of the pathologist. Where 
a typical proliferation of immature smooth muscle cells and epithelioid cells outside the normal 
muscular structures occur, associated with cyst formation, routine haematoxylin and eosin 
staining in combination with adequate clinical and radiological information is sufficient to make 
the diagnosis in most cases. Immunohistochemistry for smooth muscle actin, desmin, and 
HMB45 is an important adjunct to diagnosis. Smooth muscle actin will stain all muscular cells, 
desmin will stain the more mature smooth muscle cells. Epithelioid LAM cells and some 
immature spindle cells are generally positive for HMB45[8, 61, 67, 68]. Although HMB45 is a 
highly sensitive marker in LAM only 17-67% of LAM cells are positive and in early disease 
where only a few scattered cells are present this may be overlooked unless there is a strong 
clinical suspicion of LAM. HMB45 is particularly useful in samples obtained by transbronchial 
biopsy[61]. In rare cases, HMB45 staining is absent but the characteristic lesions are present and 
the diagnosis of LAM can still be made[8, 61]. In such cases a correlation with clinical and high-
resolution CT scan is essential to increase the confidence level of diagnosis. In about half of the 
cases oestrogen and/or progesterone receptor can be detected by immunohistochemistry[69, 70].  
 
Differential diagnosis in lung biopsy tissue 
Muscle cell proliferations can occur in emphysema[71], some variants of pulmonary 
hypertension, hypertrophic bronchitis / bronchiolitis, and some interstitial pneumonias[72] 
especially idiopathic pulmonary fibrosis. Metastasis of endometrial stromal sarcoma of the uterus 
can mimic LAM[73]. In these cases the smooth muscle cells are HMB45 negative. Metastasis of 
malignant melanoma, peripheral nerve sheath tumours of Schwann or perivascular epithelioid 
cell origin, benign metastasizing leiomyoma and metastatic leiomyosarcoma can stain positively 
with HMB45 but have a different morphologic appearance. 
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Extra-pulmonary involvement  
If lymph nodes are involved a lymph node biopsy from the retroperitoneum or mediastinum may 
be diagnostic. Where lymphatics alone are sampled the presence of characteristic immature 
smooth muscle component must be convincing to make a diagnosis of LAM. Primary lymphatic 
disorders may mimic LAM (and present with chylothorax) including pulmonary 
lymphangiomatosis, Gorham-Stout syndrome, and lymphangioleiomyoma of the thoracic 
duct[74, 75].  
 
The diagnosis of angiomyolipoma can be made by imaging in the correct context; the histologic 
diagnosis of angiomyolipoma is made by the mixture of proliferating small and medium sized 
blood vessels, perivascular epithelioid cells and fat cells and can often be made on frozen section. 
Renal cell carcinoma has been considered a feature of kidney pathology in TSC although some 
cases have been recognised recently as a carcinoma-like variant of angiomyolipoma.  
 
Recommendations / pathologic criteria and procedures for diagnosis of LAM 
1. Pathological samples from patients with suspected LAM (or any diffuse parenchymal 
lung disease) should be examined by a pathologist experienced in LAM.  
2. LAM should be considered when there is a variable predominance of cysts, multifocal, 
nodular proliferating immature smooth muscle and perivascular epithelioid cells.  
3. Immunohistochemistry for α-smooth muscle actin and HMB45 should be performed 
especially where morphologic features do not allow a secure diagnosis to be made. 
Oestrogen and progesterone receptor may be an adjunct to diagnosis. 
(Grade) expert opinion / A (Quality) expert opinion (Benefit) substantial 
(Consensus) very good 
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Radiologic criteria for diagnosis  
Characteristic features of pulmonary LAM on HRCT 
The appearance, size, and contour of lung cysts vary considerably with cysts typically ranging 
from 2-5 mm in diameter but occasionally as large as 30 mm[76, 77]. The cysts may decrease in 
size in expiratory images, indicating a communication with the airways[78]. Cysts are distributed 
evenly throughout the lungs, are usually round and generally surrounded by normal lung 
parenchyma. Cyst wall thickness ranges from barely perceptible to 2 mm thick in most series[77, 
79] but has been described as measuring up to 4 mm[76]. In some cases reticulation or ground-
glass attenuation may be seen. Small nodules are occasionally present[80], most commonly 
multifocal micronodular pneumocyte hyperplasia in patients with TSC (which may occur with or 
without LAM)[2]. Ill-defined areas of increased attenuation may result from complications such 
as haemorrhage or oedema. Sometimes ground-glass attenuation is related to proliferation of 
smooth cells in the alveolar walls. Rarely, centrilobular micronodules corresponding to smooth 
muscle cells around the bronchioles are observed. Uni or bilateral pneumothorax and chylous 
pleural effusions can be seen. Mediastinal or hilar adenopathy may be present. 
 
Differential diagnoses of LAM by HRCT scanning 
The main differential diagnosis is Langerhans cell histiocytosis (LCH). Nodules, cavitating 
nodules, and thick-walled cysts are common findings in early LCH but are very unusual in 
LAM[81]. A cystic pattern predominates in later phases[82]. Unlike LAM, in LCH the cysts are 
irregular with bizarre shapes and have a predilection for the upper lung zones and spare the 
bases[83]. In emphysema, commonly seen affecting the upper lobes in smokers, HRCT shows 
areas of low attenuation with or without visible walls, but more often the cystic areas have no 
perceptible wall. The Birt-Hogg-Dubé syndrome (BHDS) is a rare autosomal dominantly 
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inherited genodermatosis without gender predominance with features somewhat reminiscent of 
TSC including lung cysts and pneumothorax, cutaneous fibrofolliculomas, and kidney tumours. 
The BHDS is associated with germline mutations of the folliculin gene. Multiple lung cysts are 
present in about 90% and pneumothorax occurs in about 24% of patients; patients with a history 
of pneumothorax have multiple lung cysts (with a median age at first pneumothorax of 38 
years)[84]. Familial isolated primary spontaneous pneumothorax with pulmonary cysts (without 
skin and renal disease) is also associated with germline mutations in folliculin[85, 86].  
Cystic spaces can be seen in a small proportion of patients with hypersensitivity pneumonitis[87], 
and in up to 60-80% of patients with lymphocytic interstitial pneumonia[88]. Occasionally, cystic 
lung changes have been observed in amyloidosis[89], non-amyloid immunoglobulin light chain 
deposition disease[90], Marfan’s syndrome[91], cystic pulmonary metastases of sarcoma[73] and 
multiple cystic mesenchymal hamartoma[92].  
 
CT protocol for the diagnosis of LAM 
HRCT is the recommended imaging technique for the diagnosis, assessment, and follow-up of 
diffuse infiltrative lung disease including LAM[93]. Images are obtained during end inspiration 
with the patient in the supine position, without intravenous contrast. A thin collimation, high 
spatial reconstruction algorithm must be used to acquire high-quality HRCT scans. The 
acquisition may be performed with sequential scanning (images with 1mm collimation at 1-cm 
intervals) or low dose spiral multi-detector CT.  
 
Recommendations 
1. Patients with suspected LAM should have a pulmonary HRCT scan using a thin 
collimation, high spatial reconstruction algorithm.  
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2. The acquisition may be performed with sequential scanning (images with 1mm 
collimation at 1-cm intervals) or low dose spiral HRCT. (Grade) expert opinion / A 
(Quality) expert opinion (Benefit) substantial (Consensus) very good 
 
Remarks 
HRCT features characteristic of LAM are multiple thin-walled round well-defined air-filled cysts 
with preserved or increased lung volume with no other significant pulmonary involvement. In 
particular, there should be no interstitial lung disease with the exception of possible features of 
multifocal micronodular pneumocyte hyperplasia in patients with TSC. 
HRCT features compatible with pulmonary LAM are only few multiple (> 2 and ≤ 10) thin-
walled round well-defined air-filled cysts (less than 30 mm) with preserved or increased lung 
volume with no other significant pulmonary involvement, in particular, there should be no 
interstitial lung disease with the exception of possible features of multifocal micronodular 
pneumocyte hyperplasia in patients with TSC. 
 
Radiology in abdominal LAM  
Once a diagnosis of LAM is made or suspected, abdominal CT scanning can be used to detect 
angiomyolipomas, lymphangioleiomyomas or lymphadenopathy to support the diagnosis of 
LAM, to plan the management of angiomyolipomas, and to follow the evolution of the lesions. In 
a large series of abdominopelvic imaging findings in 80 patients with LAM abnormalities were 
found in up to 2/3 of patients[7]. Both ultrasound and CT are used to detect renal 
angiomyolipomas. CT is more sensitive and specific and can detect tumours less than 1 cm in 
diameter[7]. Magnetic resonance imaging (MRI) with and without fat suppression techniques 
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may be adequate for diagnosis of fat-containing tumours when iodinated contrast is 
contraindicated[94]. 
 
Criteria for radiologic diagnosis of kidney angiomyolipomas 
Ultrasound A hyper-echoic appearance at ultrasound is suggestive but not diagnostic of 
angiomyolipoma[94].  
CT Angiomyolipomas usually manifest as a tumour with fat attenuation in the renal cortex. 
Intratumoral fat with negative attenuation values is virtually pathognomonic of angiomyolipoma. 
In LAM the mean size is <1.5 cm[7]. Fat is not detectable in 5% of angiomyolipomas overall 
although an absence of fat is more common in patients with LAM[7]. If fat is not detected, close 
follow-up of these lesions with US or unenhanced CT is recommended. In case of rapid growth, 
an image-guided biopsy may be considered. 
MRI Fat containing tumours have high signal intensity on T1-weighted images that is similar to 
that of subcutaneous and retroperitoneal fat and demonstrated saturation of signal on fat-
saturation images.  
Recommendations for abdominal CT scanning in LAM 
1. All patients with LAM or suspected LAM should have an abdomino-pelvic CT at 
diagnosis or during workup to identify angiomyolipomas and other abdominal lesions. 
2. The abdomen should be scanned contiguously with 3mm collimation or less, before 
and after the intravenous administration of non-ionic contrast.  
3. Since a proven therapeutic intervention is not currently available for 
lymphangioleiomyomas, screening of asymptomatic patients for 
lymphangioleiomyomas during the course of the disease should not be performed.  
4. Patients with abdominal symptoms should be evaluated for the presence of 
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lymphadenopathy or lymphangioleiomyomas by CT scanning. 
(Grade) C (Quality) low (Benefit) intermediate (Consensus) very good 
Screening for meningioma in patients with sporadic LAM  
 
Patients with LAM have an increased risk of meningioma. As meningiomas express progesterone 
receptors and their growth may be promoted by progesterone; these lesions should be identified 
especially in patients receiving progesterone. Brain imaging is also useful in the workup of 
possible TSC in patients with LAM. 
Recommendations 
1. Brain MRI as a baseline evaluation may be useful for comparison during follow up and 
should be performed in the presence of symptoms compatible with meningioma. (Grade) 
C (Quality) low (Benefit) intermediate (Consensus) very good 
2. Brain MRI for screening meningioma should be performed in women with LAM 
receiving progestative drugs or planned to receive such treatment. (Grade) expert 
opinion / B (Quality) expert opinion (Benefit) intermediate (Consensus) very good 
 
Work-up for TSC in patients with LAM  
Patients presenting with apparent sporadic LAM may have TSC. As TSC has a highly variable 
phenotype and 2/3 of cases arise as spontaneous mutations the diagnosis can be overlooked. Data 
on the prevalence of TSC in patients presenting with LAM is limited as many of the earlier series 
did not formally examine their patients for TSC and many excluded patients with TSC LAM 
from their analysis[4]. 
The diagnosis of TSC has important implications for patients and their families. Thorough 
evaluation of patients with TSC is recommended to avoid complications of specific lesions such 
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as sub-ependymal giant cell astrocytoma[37], and renal morbidity from haemorrhage, carcinoma 
and renal failure[95-98]. In addition the diagnosis of TSC has significant implications for genetic 
counselling in women contemplating pregnancy. Diagnosis of TSC may require the input of more 
than one specialist. Diagnostic criteria for TSC and recommendations for assessment of patients 
are provided in appendix 2[55] . 
Conclusion 
Patients diagnosed with LAM may have TSC and making this diagnosis has important 
implications for patients and their families. Patients should undergo a full history and physical 
examination to exclude TSC. Where doubt exists the patient should be referred to a clinical 
geneticist for further evaluation. 
Recommendations 
1. Patients presenting with LAM should have a thorough history and family history taken 
concerning the manifestations of TSC. Physical examination should include the skin, 
retina and nervous systems by a physician familiar with the manifestations of TSC. 
(Grade) B (Quality) low (Benefit) substantial (Consensus) very good 
2. Patients with LAM and bilateral angiomyolipomas and other patients where doubt 
remains should be referred to a clinical geneticist for full evaluation. (Grade) D (Quality) 
low (Benefit) substantial (Consensus) very good 
3. Routine genetic analysis of patients with sporadic LAM is not of benefit and should not 
be performed. (Grade) D (Quality) low (Benefit) negative (Consensus) very good 
 
 
Lung function testing 
To be informative, lung function tests need to be reproducible, abnormal in disease, and 
     
 23 
deteriorate with disease progression. TLCO and FEV1, have been correlated with histological[26] 
and CT grading[27] in large series of patients with LAM. Most longitudinal studies of lung 
function in LAM have examined change in FEV1 and TLCO over time[4, 29, 30]. Mean rate of 
decline in FEV1 and TLCO vary between 69-118 ml/yr and 0.69-0.9 ml/min/mmHg 
respectively[4, 29, 30]. All studies showed a large range in rate of decline between individual 
patients. Various studies have used these data in addition to pathology and imaging in an attempt 
to predict rate of decline in individuals. Total lung capacity and residual volume measured by 
body plethysmography have not been studied in detail; however as irreversible airflow 
obstruction and lung cysts are often present this may provide further information.   
Conclusion 
FEV1 and TLCO correlate with CT and histological abnormalities in LAM, and change over time 
as the disease progresses. TLCO is abnormal in more patients than FEV1 and may be a more 
sensitive indicator of early disease. Cardiopulmonary exercise testing may provide additional 
information especially in patients with milder disease but is more difficult to obtain and perform 
in a reproducible manner. The rate of decline in FEV1 and TLCO varies between individuals and 
it remains difficult to predict the clinical course in individuals and hence how often to repeat lung 
function. Most physicians initially perform standard lung function tests every 3-6 months. In 
patients with stable disease; after a period of observation this may be increased to yearly 
intervals.  
Recommendations 
1. Spirometry, bronchodilator testing, and TLCO should be performed in the initial 
evaluation of patients with LAM (including TSC-LAM). (Grade) B (Quality) low 
(Benefit) substantial (Consensus) very good 
2. FEV1 and TLCO should be performed to assess disease progression and response to 
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treatment. (Grade) B (Quality) low (Benefit) substantial (Consensus) very good 
3. Lung function tests should be repeated every 3 - 6 months in patients with progressive 
disease and every 6 - 12 months in those with more stable disease as determined by a 
period of observation of one year. (Grade) C (Quality) low (Benefit) intermediate 
(Consensus) very good  
 
Arterial blood gas measurement  
Arterial hypoxaemia is common in LAM[20, 25]. In the NIH registry of 214 patients mean PaO2 
was 10.85 kPa and mean PaCO2 4.5 kPa[24]. This study included a large number of patients with 
early disease. Hypercapnia is rare at presentation and uncommon during the course of the 
disease[3, 99] being seen in 3 of 25 patients directly before lung transplant[100].  
Conclusion 
Blood gases do not provide useful information above that obtained by oximetry in the assessment 
of patients with mild to moderate disease. However they provide useful baseline data and in 
advanced disease may be useful to define the indication for oxygen therapy in patients, especially 
for transplant evaluation and to exclude hypercapnia.  
Recommendations 
1. Blood gases may be performed at initial evaluation of patients with LAM to obtain a 
baseline value, and in the assessment of patients with severe disease including before 
transplant referral. (Grade) expert opinion / A (Quality) expert opinion (Benefit) 
substantial (Consensus) very good 
2. Blood gases should be performed to assess the indication for oxygen therapy in patients 
with advanced disease. (Grade) expert opinion / A (Quality) expert opinion (Benefit) 
substantial (Consensus) very good 
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Cardiopulmonary exercise testing and six minute walk test (6MWT) 
Patients with LAM have limitation of their exercise performance. Impaired performance and 
reduced maximal oxygen consumption (VO2 max) on cardiopulmonary exercise testing may 
occur before abnormalities are detected in standard lung function tests[28]. Although the six 
minute walk test (6MWT) is commonly used to assess patients with LAM no specific studies 
have examined its use in this context. As in other lung diseases the 6MWT is likely to provide 
evidence of disability and its decrease might reflect disease progression[101].  
Conclusion 
Exercise performance and VO2 max are impaired in patients with LAM. As in other lung 
diseases, the 6MWT is likely to be helpful in evaluating exercise performance in patients with 
LAM.  
Recommendations 
1. Cardiopulmonary exercise testing may be performed to provide additional information 
over standard lung function tests in symptomatic patients. (Grade) C (Quality) low 
(Benefit) small / weak (Consensus) very good  
2. The 6MWT may be performed in the evaluation of disability in LAM, disease 
progression, and response to treatment in symptomatic patients (Grade) expert opinion / 
B (Quality) expert opinion (Benefit) intermediate (Consensus) very good 
 
Screening for pulmonary hypertension 
Despite being well documented in other diffuse parenchymal lung diseases, pulmonary 
hypertension has not been reported frequently in cohorts of patients with LAM. In a systematic 
study of echocardiography in 120 patients with LAM only eight had pulmonary hypertension at 
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rest although exercise induced pulmonary hypertension was observed in 56. In most cases this 
was associated with exercise induced desaturation[28]. No data are available on the efficacy of 
treatment of pulmonary hypertension in LAM.  
Recommendations 
1. Screening for pulmonary hypertension is not recommended in patients with non-severe 
LAM. (Grade) I (Quality) low (Benefit) conflicting (Consensus) very good 
2. Estimation of pulmonary artery pressure by echocardiography may be performed in 
patients with severe disease and those requiring long-term oxygen therapy. It should be 
performed in those considered for lung transplantation. (Grade) C (Quality) low 
(Benefit) intermediate (Consensus) very good 
 
SCREENING FOR LAM IN AT RISK GROUPS 
 
The estimated numbers of patients with LAM based on prevalence in registries and the long delay 
between the first symptom and diagnosis in many patients suggest that in many patients LAM is 
either not detected for many years or patients are wrongly diagnosed with another disease. 
Although no treatment has been proven to affect the clinical course of LAM, patients with LAM 
may benefit from several low risk interventions including education on the symptoms of 
pneumothorax, avoidance of oestrogen containing treatments, prophylactic vaccination against 
influenza and pneumococcus, smoking cessation measures and monitoring to detect progression 
at an earlier stage, possibly allowing patients to participate in clinical studies or use symptomatic 
treatments earlier in their disease course.  
Is CT indicated in women with apparently spontaneous pneumothorax? 
Guidelines developed for the management of spontaneous pneumothorax do not recommend the 
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routine use of chest CT imaging for patients with a first-time pneumothorax. CT may be 
indicated to evaluate the presence of suspected pulmonary disorders not detectable on standard 
radiographs. The rate of recurrence for secondary pneumothorax is about 40-50% (about 30% in 
primary pneumothorax). The rate of recurrence of pneumothorax in LAM is about 75%. The 
estimated prevalence of LAM in women with recurrent spontaneous pneumothorax based on the 
relative frequencies of these conditions is between 0.07 and 1.4%. 
Conclusion 
The low prevalence of LAM does not justify chest CT for diagnosing LAM at first 
pneumothorax. It may be justified at the second pneumothorax, and should be done at the third 
(and more) pneumothorax, especially in non smoking women, and if symptoms (e.g. dyspnoea) 
are present before the pneumothorax. 
Recommendations 
1. Chest CT for patients with a first-time pneumothorax should not be performed routinely. 
(Grade) I (Quality) low (Benefit) conflicting (Consensus) good 
2. Chest CT may be indicated to evaluate the presence of LAM that is suspected clinically 
but is not apparent on standard radiographs. (Grade) C (Quality) low (Benefit) small / 
weak (Consensus) good 
3. The panel did not achieve consensus regarding the utility of chest CT scans for evaluating 
patients with recurrent pneumothoraces, persistent air leaks, or planned surgical 
interventions. (Grade) I (Quality) low (Benefit) conflicting (Consensus) none 
 
 
Should women with TSC undergo screening for LAM by high resolution CT scan?  
Prevalence of TSC in LAM  
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Symptomatic LAM in TSC (TSC-LAM) is more prevalent than in the general population. In the 
largest retrospective survey of the prevalence of LAM in TSC, 388 patients seen at a tertiary 
referral centre for TSC over a 43 year period were evaluated. Nine (2.3%) were found to have 
symptomatic LAM[53]. Recently three studies systematically examined the prevalence of TSC-
LAM by using HRCT to screen both symptomatic and asymptomatic patients with TSC for cystic 
lung disease. These studies found that 26 - 39% of patients had lung cysts consistent with 
LAM[2, 51, 52].  
Conclusion 
There is a high prevalence of LAM in women with TSC. The significance of this observation is 
unknown as most of these women have no symptoms of lung disease and the natural history of 
LAM detected by screening in TSC is not known. However detection of LAM in otherwise 
asymptomatic patients may allow earlier recognition and treatment of symptoms if they occur. In 
addition it may be helpful for women with LAM to avoid oestrogen containing medication and 
receive additional pre-pregnancy counselling. The high prevalence of LAM in TSC suggests that 
women with TSC should be examined for LAM. As clinical examination, chest radiography and 
lung function tests may all be normal in the presence of LAM. HRCT is the investigation of 
choice.  
Recommendations 
1. Women with TSC should undergo screening for LAM by HRCT of the thorax at the age 
of 18 and if negative again at the age of 30-40 years. (Grade) C (Quality) low (Benefit) 
intermediate (Consensus) very good 
2. HRCT should be repeated if persistent respiratory symptoms develop. (Grade) C 
(Quality) low (Benefit) intermediate (Consensus) very good 
3. Women with TSC should undergo HRCT of the thorax in the presence of otherwise 
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unexplained respiratory symptoms. (Grade) B (Quality) low (Benefit) small / weak 
(Consensus) very good 
 
Should men with TSC be screened for LAM by HRCT?  
TSC has no sex predilection; however TSC-LAM occurs almost exclusively in women. There are 
only a few case reports describing LAM in men with TSC[5, 102]. Screening of 10 men with 
TSC using HRCT did not reveal any cases of LAM[52]. It is likely that LAM is rare in men with 
TSC. Screening is unlikely to detect significant numbers of cases. In addition the potential benefit 
of diagnosing early asymptomatic disease would be less likely to benefit men due to a lower 
likelihood of being exposed to oestrogen.  
Conclusion 
LAM can occur in men with TSC but is very rare. As men are less likely to be exposed to 
oestrogen containing treatments early diagnosis of LAM is less likely to be of benefit to patients. 
Recommendations 
1. Men with TSC and otherwise unexplained respiratory symptoms should be investigated as 
dictated by their symptoms; this may include HRCT scanning. (Grade) C (Quality) low 
(Benefit) intermediate (Consensus) very good 
2. Men without respiratory symptoms should not be screened for LAM with HRCT (Grade) 
D (Quality) low (Benefit) negative (Consensus) very good 
 
Is screening for LAM needed in women with sporadic angiomyolipoma? 
Screening for LAM may be needed in women with angiomyolipoma and no pulmonary 
symptoms or manifestations of LAM if the prevalence of LAM in this population is high. 
Surprisingly, in the published series of angiomyolipoma, sporadic LAM has been reported in 
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only 1 patient[103], whereas the prevalence of angiomyolipomas in LAM is 40-50 % of patients 
when screened by CT[7]. The prevalence of angiomyolipomas in TSC is about 80%[38, 104, 
105]. Of these, bilateral angiomyolipomas occur in 86% of cases of TSC and angiomyolipoma 
and in only 12% of patients with sporadic angiomyolipoma. TSC patients have larger tumours 
and more frequent haemorrhage than those with sporadic angiomyolipoma[103, 106-109]. Case 
series suggest the lower and upper limits of prevalence of LAM in TSC are 10 and 39% 
respectively, the lower and upper limits prevalence of LAM in women with angiomyolipoma are 
respectively 1.8 and 7.1%. As TSC is present in 63.7% of bilateral angiomyolipomas, the lower 
and upper limits of prevalence of LAM in patients with bilateral angiomyolipomas are 6.4 and 
24.8% respectively. 
Recommendations 
1. In patients with unilateral angiomyolipomas, no clinical features of TSC and no 
pulmonary symptoms, screening for LAM by HRCT may be performed. 
2. In patients with bilateral angiomyolipoma screening for TSC should be performed, with 
further LAM screening if TSC is present. (Grade) B (Quality) low (Benefit) small / 
weak (Consensus) very good 
 
PROGNOSIS 
 
Estimation of prognosis 
The clinical course of LAM is highly variable with some patients developing progressive airflow 
obstruction whilst others remain stable for many years. In addition to worsening airflow 
obstruction, patients may have intermittent pneumothorax and in some cases chylous collections. 
Patients with sporadic LAM generally develop progressive airflow obstruction. Two national 
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studies have shown that FEV1 declines at around 120 ml/yr on average (approximately four times 
the normal rate), although the variation about this mean value was large in both studies[3, 4]. In a 
large study from a tertiary centre decline in FEV1 was slower at 70 ml/year however this study 
included relatively few patients with severe disease[30]. This clinical variation means it is 
difficult to accurately assess the prognosis of an individual patient at the onset of disease. 
Studying a cohort of patients, it has been shown that at 10 yrs from the onset of symptoms, 55% 
of patients are more breathless than their peers or have to stop when walking at their own pace on 
the flat, and 10% are housebound due to dyspnoea[65].  
To date, all analyses of survival in LAM have been based on retrospective case series, with the 
potential bias of missing older and more severe cases. In the two oldest series with cases 
diagnosed before 1973 the 10 yr survival was respectively 24 and 30%[19, 110]. In the three 
most recent series with cases diagnosed from 1973 to 2003, the 10-yr survival was 79, 71 and 
91%[3, 57, 65]. The most likely causes of the apparent improvement in survival are earlier 
diagnosis, especially since CT became available, a better knowledge of the disease and increased 
clinical awareness, as reflected by an increasing number of publications and diagnosed cases[3, 
111]. The main therapeutic interventions, which could also have contributed to a true increase in 
survival in LAM are lung transplantation and possibly long-term oxygen therapy.  
A number of studies have attempted to predict the rate of disease progression from pathological, 
physiological, imaging and clinical data: these studies are discussed below. For the purpose of 
estimation of prognosis at diagnosis, a predictor is defined as an explanatory variable measured at 
diagnosis. Prognosis is defined as a variable indicating disease severity measured after initial 
evaluation. 
Histological factors 
Relationships between histological features of pulmonary LAM at diagnosis and survival have 
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been analysed in two retrospective studies. Although using different scoring systems, both studies 
evaluated the relative proportions of abnormal lung tissue, cystic destruction and LAM cell 
invasion. In both cases, a greater proportion of abnormal lung and cystic change were correlated 
with shorter survival. The percentage of hemosiderosis was found to predict survival in one study 
but not in a second. The extent of LAM cell proliferation did not predict survival. [25, 57]. 
Clinical factors 
Relationships between clinical features at diagnosis and either survival or decline in lung function 
have been evaluated in three retrospective studies. In one, lower FEV1/FVC and higher total lung 
capacity (TLC) at diagnosis was associated with shorter survival[25]. In another, a positive 
response to β-agonists correlated with more rapid decline in FEV1[26]. The third, found that 
lower initial TLCO and KCO, predicted more rapid FEV1 decline[29]. None of these factors has 
been evaluated prospectively. 
TSC-associated and sporadic LAM  
Data from retrospective studies suggest that for a similar age at diagnosis, pulmonary 
involvement appears less severe in TSC-LAM than in sporadic-LAM[24, 111]. However no at 
risk population for sporadic LAM has been screened in the same way as for TSC-LAM. It is not  
therefore possible to determine if this apparent difference is due to a number of undiagnosed 
patients with asymptomatic sporadic LAM. Cross sectional data suggest that progression of lung 
disease occurs in TSC-LAM, but whether disease activity and rate of progression differ between 
TSC-LAM and S-LAM is currently unknown. Longitudinal studies are needed to address this 
issue. 
Conclusions  
Some histological and lung function variables have been found to be predictive of either survival 
     
 33 
or more rapid deterioration of lung function at diagnosis. However, these predictors have not 
been validated prospectively. Moreover, some of these variables reflect more advanced disease at 
the time of diagnosis, and thus a greater probability of death. They do not necessarily provide 
information about disease activity and rate of progression and should not, on their own, influence 
clinical decisions at the present time. TLCO and FEV1 are likely to be the best current indicators 
of disease progression and survival. Patients with TSC-LAM may have a more indolent course 
than those with sporadic LAM but more studies are required to address this issue. 
Recommendations 
1. Lung biopsy does not provide prognostic information and should not be performed for 
this purpose alone. (Grade) D (Quality) low (Benefit) negative (Consensus) very good 
2. Disease progression may be evaluated by repeating lung function tests at 3-6 monthly 
intervals during the first year following diagnosis then at 3-12 monthly intervals 
depending on the severity and progression of the disease. (Grade) C (Quality) low 
(Benefit) small / weak (Consensus) very good 
 
Follow up of patients with TSC-LAM with no pulmonary symptoms 
Sporadic LAM is generally a progressive disease characterised by deteriorating lung function[4, 
30]. In patients with TSC-LAM and progressive disease regular follow up and serial lung 
function is recommended to detect and intervene early where the clinical picture changes. No 
prospective studies have analysed the rate of decline of lung function in patients with TSC-LAM, 
particularly when LAM has been identified in patients with no symptoms. At the current time 
there are no treatments which have been shown to reduce the rate of decline of lung function in 
LAM. However as in any patient with LAM, a baseline evaluation with spirometry and 
measurement of TLCO is recommended at diagnosis. 
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Conclusions 
In patients with TSC-LAM and minimal symptoms the risk of progressive decline in lung 
function appears to be lower than in those with sporadic LAM. As no therapy is effective for 
early disease the benefit of regular follow up and lung function measurement are not clear. 
Recommendations 
1. Regular follow up by a respiratory specialist or serial lung function studies may not be 
required for patients with TSC-LAM with normal lung function after initial evaluation 
and who have been stable after a period of observation of one year. Follow up respiratory 
evaluation and lung function should be performed if respiratory symptoms develop. 
(Grade) expert opinion / C (Quality) expert opinion (Benefit) small / weak 
(Consensus) very good  
2. Other health professionals involved in the care of patients with TSC and patients 
themselves should be informed that patients experiencing respiratory symptoms should be 
seen by a respiratory specialist. This may be in an information document given to patients 
and general physicians. (Grade) expert opinion / C (Quality) expert opinion (Benefit) 
small / weak (Consensus) very good  
 
MANAGEMENT 
 
General advice and interventions 
In common with other pulmonary diseases, patients with LAM should be encouraged to maintain 
a normal weight and refrain from smoking. The diagnosis of an orphan disease and its 
consequences often leave patients with a feeling of isolation. Patients groups can help with these 
issues and other practical matters.  
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Advice for patients on pneumothorax 
LAM is associated with an increased risk of pneumothorax. About 40% of women with LAM 
have a pneumothorax at presentation and 66% of patients have a pneumothorax during the course 
of the disease. LAM is associated with an increased risk of recurrence of pneumothorax after a 
first episode. The estimated rate of recurrence of pneumothorax in LAM is approximately 75%. 
 
Recommendation 
1. Patients with both sporadic and TSC-LAM including those with no or minimal symptoms 
must be warned of the risk of pneumothorax and told to seek urgent medical attention in 
the event of symptoms of pneumothorax. (Grade) A (Quality) fair (Benefit) substantial 
(Consensus) very good 
 
Advice for patients and management of pregnancy 
There are a number of reports of women presenting with LAM during pregnancy, usually with a 
pneumothorax and occasionally chylous pleural effusion[112-116]. There are also reports of an 
increased risk of pneumothorax during pregnancy[10]. As a result of these initial case reports a 
recent survey has shown that 30% of women with LAM are worried about the effect of 
pregnancy on the disease and 25% have been told by a physician to avoid pregnancy[117]. 
Despite this, two thirds of women with LAM have been pregnant either before or during their 
disease[24]. There is no evidence that pregnancy increases the risk of developing LAM in 
patients with TSC[118]. Patients with TSC-LAM have the additional issue that their baby has a 
50% risk of inheriting TSC. There are a number of case reports documenting the rupture of 
angiomyolipoma during pregnancy, although the data are limited to case reports and the relative 
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risk in pregnancy is not established[119-122].  
Conclusion 
It is likely that pregnancy in LAM is associated with an increased risk of pneumothorax and 
chylothorax, which can on occasion require surgery. It is not clear if pregnancy accelerates the 
decline in lung function. Although no clear evidence exists it is likely that patients with poor 
baseline lung function are less likely to tolerate a pneumothorax or chylous effusion if they were 
to occur during pregnancy than those with good pre-pregnancy lung function. Although 
infrequent there may be an increased risk of bleeding from angiomyolipoma during pregnancy.  
Recommendations 
1. To become pregnant is the patients’ decision. However all patients, including those with 
few or no symptoms, should be informed that there is a greater risk of pneumothorax and 
chylous effusion during pregnancy. Those with recurrent pneumothorax or effusion 
outside pregnancy and those with poor baseline lung function are at greater risk during 
pregnancy. (Grade) expert opinion / B (Quality) expert opinion (Benefit) 
intermediate (Consensus) very good 
2. Women with LAM who are pregnant should receive information, ideally pre-pregnancy 
or as soon after conception as feasible to warn of the risk of pneumothorax, effusion and 
bleeding from angiomyolipoma.  (Grade) expert opinion / B (Quality) expert opinion 
(Benefit) intermediate (Consensus) very good 
3. Patients with tuberous sclerosis should further receive genetic counselling prior to 
conception. (Grade) A (Quality) good (Benefit) substantial (Consensus) very good 
4. Patients should be monitored during pregnancy by both a pulmonary physician and an 
obstetrician informed about LAM.  (Grade) expert opinion / B (Quality) expert opinion 
(Benefit) intermediate (Consensus) very good 
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5. It may be appropriate to discourage patients with severe disease from becoming pregnant, 
this counsel being given on an individual basis (Grade) expert opinion / B (Quality) 
expert opinion (Benefit) intermediate (Consensus) very good 
 
Avoidance of oestrogen including the contraceptive pill and hormone replacement 
Although no clear evidence links oestrogen to more rapid progression of LAM the supposition 
that LAM is oestrogen dependent comes from several observations. Firstly, sporadic LAM is 
(almost) exclusively a disease of women[1, 59]. In TSC-LAM the overwhelming majority of 
patients are women[2, 51, 52] with only a very small number of case reports in men[5, 102]. A 
number of case reports describe complications of LAM during administration of exogenous 
oestrogens[123-125]. In perhaps the most relevant study to this question use of the oral 
contraceptive pill in women with LAM is associated with an earlier onset of symptoms[126]. 
Further, two retrospective studies have shown a reduced rate of decline in lung function in post-
menopausal, compared with pre-menopausal women although this was statistically significant in 
only the larger study[4, 30]. In addition, in a study of UK patients with LAM five of 57 presented 
after the menopause, of whom four had been taking oestrogen containing hormone replacement 
therapies up to presentation.  
Conclusions 
Exogenous oestrogens may promote the progression of pulmonary LAM in at least some cases.  
Recommendation 
1. Women with LAM should avoid oestrogen containing treatments including the combined 
oral contraceptive pill and hormone replacement therapy. (Grade) C (Quality) low 
(Benefit) intermediate (Consensus) very good 
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Information for patients concerning air travel 
The high frequency of pneumothorax in LAM and reports of pneumothorax occurring in flight 
has resulted in women with LAM being advised not to travel by air. In a recent survey of 454 
flights by 276 patients the risk of pneumothorax during flight was 2% and in half of these 
patients symptoms had begun before travel. Other problems included hypoxaemia and 
dizziness[127]. Although the patients in the study were slightly less dyspnoeic than patients who 
never flew this difference was not significant and the numbers of patients who had had a 
pneumothorax previously was similar to all patients with LAM[127].  
Conclusions 
Patients with sporadic and TSC-LAM with well preserved lung function do not need to take 
specific precautions or avoid air travel. They should be advised not to board a flight if they have 
new respiratory symptoms. Those with advanced disease should be evaluated for the need for 
oxygen during flight to prevent hypoxemia and as they are less likely to tolerate pneumothorax. 
Recommendations 
1. Patients with sporadic or TSC-LAM and minimal symptoms should not be discouraged 
from air travel. They should be warned that they should not travel if new respiratory 
symptoms have not been evaluated. (Grade) C (Quality) low (Benefit) intermediate 
(Consensus) very good 
2. Patients with advanced disease should be evaluated for the need for oxygen during flight 
and should not travel if new respiratory symptoms have not been evaluated. Those for 
whom an untreated pneumothorax may have serious consequences should consider 
alternatives to air travel. (Grade) C (Quality) low (Benefit) intermediate (Consensus) 
very good 
3. Patients with a known untreated  pneumothorax, or a pneumothorax treated within the 
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previous month, should not travel by air (Grade) B (Quality) low (Benefit) substantial 
(Consensus) very good 
 
Pulmonary rehabilitation 
Pulmonary rehabilitation is aimed at reducing functional impairment and disability of patients 
with chronic lung disease[128]. There have been no specific studies examining the impact of 
pulmonary rehabilitation in LAM; evidence supporting pulmonary rehabilitation in LAM may be 
extrapolated from other diseases including COPD. The British Thoracic Society statement on 
pulmonary rehabilitation states: ‘Although most patients will have COPD, the benefits of 
rehabilitation may apply to all patients with dyspnoea from respiratory disease. The introduction 
of rehabilitation becomes appropriate when patients become aware of their disability. 
Rehabilitation should be considered at all stages of disease progression when symptoms are 
present and not at a predetermined level of impairment. This would usually be MRC dyspnoea 
grade 3 (walk slower than people of the same age on the level or have to stop when walking at 
own pace on the level) or above’[128].  
Conclusion 
Pulmonary rehabilitation is indicated in patients with LAM who are limited by dyspnoea. 
Recommendation 
1. Pulmonary rehabilitation may be offered to patients with LAM who are limited by 
dyspnoea. (Grade) expert opinion / B (Quality) expert opinion (Benefit) intermediate 
(Consensus) very good 
 
Influenza and pneumococcal vaccination  
Although the effect of prophylactic vaccination in patients with LAM has not been tested, by 
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analogy with COPD, it may be proposed to patients with LAM and impaired lung function[129]. 
Recommendation 
1. Influenza and pneumococcal vaccination should be offered to patients with LAM. 
((Grade) expert opinion / B (Quality) expert opinion (Benefit) intermediate 
(Consensus) very good 
 
Assessment and management of osteoporosis 
One study of 211 patients has evaluated bone mineral density (BMD) in LAM[130]. Decreased 
BMD was found in 70% of patients, and correlated with increasing severity of lung disease, age 
menopause, and oophorectomy. Progesterone treatment was not associated with an effect on 
BMD but bisphosphonate-treated patients had lower rates of decline in lumbar spine BMD and T-
scores than untreated patients.  
Conclusions 
In view of the rapid deterioration in BMD observed after lung transplantation, early initiation of 
therapy for osteoporosis in LAM patients with severe lung disease and osteopenia at any bone 
site is recommended. In addition to pharmacologic therapy, weight-bearing exercise and strength 
training should be encouraged because of the growing evidence that exercise improves bone 
density. 
Recommendations 
1. Patients with LAM, especially post-menopausal, should undergo periodic evaluation of 
BMD. (Grade) B (Quality) low (Benefit) substantial (Consensus) very good 
2. Those with osteoporosis should be treated as other patients with osteoporosis. (Grade) B 
(Quality) low (Benefit) substantial (Consensus) very good 
3. In view of the rapid deterioration in BMD observed after lung transplantation, aggressive 
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therapy for osteoporosis should be initiated early in LAM patients with severe lung 
disease and osteopenia at any bone site. In addition to pharmacologic therapy, weight-
bearing exercise and strength training should be encouraged because of the growing 
evidence that exercise improves bone density. (Grade) B (Quality) low (Benefit) 
substantial (Consensus) very good 
 
Drug therapy 
 
Inhaled bronchodilators  
Patients with LAM are often treated with inhaled bronchodilators because these provide a 
symptomatic improvement. 20-24% of patients meet standard criteria for bronchodilator 
responsiveness[8, 26]. There have been no studies of the efficacy of inhaled corticosteroids in 
LAM although some patients have been treated with these drugs, generally in combination with 
β-agonists. Airway inflammation in the form of bronchiolitis is observed in LAM and could be a 
potential target of inhaled corticosteroids although no association between bronchiolar 
inflammation and bronchodilator reversibility has been observed[26]. As asthma is common in 
the general population it is probable that some patients with LAM will also have asthma. 
Conclusion 
Patients with LAM are frequently prescribed and continue to take inhaled bronchodilators. One 
quarter of patients respond to inhaled bronchodilators according to standard objective criteria and 
more may obtain some clinical benefit. Patients who respond to bronchodilators tend to have 
airflow obstruction and have a greater rate of decline in FEV1. Although bronchiolar 
inflammation is seen in some patients the efficacy of inhaled corticosteroids in LAM has not 
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been assessed.  
Recommendation 
1. Inhaled bronchodilators should be trialled in patients with airflow obstruction and 
continued if a response is observed. (Grade) B (Quality) low (Benefit) substantial 
(Consensus) very good 
 
Hormone therapy - Progesterone 
Progesterone treatment was initially described for LAM in 1985[131] and has been the most 
commonly used hormone treatment for LAM. Progesterone was being used by 55% of patients 
on the NHLBI LAM registry[24]. There have been no randomised controlled trials or prospective 
studies of progesterone for LAM. Several studies have compared progesterone treated patients 
with untreated patients. In one study progesterone treated patients had a lower rate of decline in 
TLCO and a trend towards a lower rate of decline in FEV1 than non-treated patients. However 
this effect was not sustained after two years[4]. Moreover, the patients in the progesterone treated 
group had lower baseline FEV1 and TLCO than the untreated patients[4]. In a larger study where 
age and initial lung function were allowed for in a more complex statistical model, the rate of 
decline in FEV1 was more rapid in progesterone treated, than in untreated patients. Intramuscular 
progesterone was associated with a slower decline than oral progesterone although none of these 
differences was significant[30]. Other smaller studies showed no difference in progesterone 
treated patients than controls[11] and in a further retrospective study looking at dyspnoea as an 
outcome rather than lung function, progesterone treated patients had faster progression of 
dyspnoea than untreated patients[65]. 
Conclusions 
There are no randomised placebo controlled trials of progesterone in LAM. There are a limited 
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amount of data from case series and case reports suggesting it to be effective at least in the short 
term in some patients. However drawing conclusions from case reports is prone to bias as 
positive outcomes are more likely to be reported than harmful or ineffective treatments. Attempts 
to formally examine the effect of progesterone are also limited by selection bias since more 
rapidly declining patients are treated with progesterone. Such studies have shown either no effect 
or worsening of lung function or dyspnoea in the progesterone treated patients and in one case a 
non-sustained reduction in rate of decline in TLCO.   
Recommendations 
1. Oral or intramuscular progesterone should not be used routinely in patients with LAM.  
(Grade) I (Quality) low (Benefit) conflicting (Consensus) very good 
2.  In patients with rapid decline in lung function or symptoms, intramuscular progesterone 
may be trialled. (Grade) C (Quality) low (Benefit) small / weak (Consensus) very good 
3. If used, progesterone may be given for 12 months with clinical evaluation and lung 
function at 3 monthly intervals. If lung function and symptoms continue to decline at the 
same rate on progesterone treatment after one year, progesterone should be withdrawn.  
(Grade) expert opinion / C (Quality) expert opinion (Benefit) small / weak 
(Consensus) very good 
 
Hormone therapy - other anti-oestrogen interventions 
Various anti-oestrogen strategies have been used to treat LAM. Treatments other than 
progesterone have largely been used as second line treatment or in combination with 
progesterone and cannot be formally analysed. Case reports have described the use of 
oophorectomy[132-136], tamoxifen[137-140] and GnRH agonists[141-143] all with varying 
outcomes. These reports are difficult to evaluate as the patients are a heterogeneous group with 
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different rates of disease progression and periods of decline and stabilisation. In addition, many 
of the interventions have been used in combination with other treatments, at a range of doses and 
durations. Finally, as previously stated, case reports are much more likely to report favourable 
rather than unfavourable outcomes leading to bias. In an attempt to avoid case reporting bias the 
following data comprises only the effect of these interventions in unselected patients from 
registries: seven received oophorectomy alone, two stabilised, one improved; tamoxifen 
stabilised disease in five of fourteen patients but has exacerbated LAM in another report[3, 20, 
25, 144]. A significant number of these patients received combinations of treatment although no 
combinations appeared especially effective. One recent open label study that examined 11 
patients treated with the GnRH agonist triptorelin found that no patients improved and the drug 
was associated with a reduction in bone mineral density[145]. 
Conclusion 
No confident data exist on the efficacy of oophorectomy, GnRH agonists or anti-oestrogens in 
LAM. A small number of reports suggest oophorectomy and tamoxifen may be associated with 
stabilisation of the disease. Due to the morbidity associated with surgical oophorectomy and a 
lack of clear evidence of benefit, oophorectomy cannot be recommended for LAM alone. Similar 
oestrogen levels as obtained after oophorectomy may be obtained with GnRH agonists although 
there is no evidence for their benefit in LAM. 
Recommendation 
1. Hormone treatments other than progesterone should not be used in patients with LAM.  
(Grade) I (Quality) low (Benefit) conflicting (Consensus) very good 
 
mTOR inhibitors 
Inherited mutations of the TSC-1 or TSC-2 genes cause TSC while acquired (somatic) mutations 
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of either gene are associated with sporadic LAM. Mutations of TSC-1 and TSC-2 are associated 
with activation of the mTOR pathway. The mTOR inhibitors sirolimus and everolimus block 
mTOR signalling by mTOR complex 1 and reduce mTOR-mediated proliferation and growth of 
LAM cells in vitro.  
One prospective, uncontrolled, open-label, phase II clinical trial has shown that sirolimus reduced 
mean angiomyolipoma volume at 12 months by 53 +/- 27% of the baseline value (p<0.001) in 
patients with TSC or sporadic LAM. Of the 25 patients enrolled, 6 had TSC-LAM and 5 
sporadic-LAM. During sirolimus therapy, the mean forced expiratory volume in one second 
(FEV1) increased by 118 +/- 330 ml (p=0.06) and there were significant improvements in FVC 
and residual volume. Improvements in angiomyolipoma volume and pulmonary function were 
reduced in the year following treatment but not back to baseline values[14]. Interim analysis of 
another prospective, multicenter, phase-II open-label clinical trial in patients with TSC (7 
patients) or sporadic-LAM (6 patients) showed a similar reduction in angiomyolipoma volume 
after 12-month therapy with sirolimus[15]. No clear improvement in lung function was observed. 
In both studies adverse events were common and included frequent aphthous ulcers, diarrhoea 
and upper respiratory infections.  
As sirolimus impairs wound healing and has been associated with an increased risk of bronchial 
anastomotic leakage after transplantation[146] it is standard practice to withhold sirolimus prior 
to surgery and transplant procedures. 
Conclusions 
There are currently no reports from randomised placebo controlled trials of mTOR inhibitors in 
LAM. Two prospective open-label clinical trials suggest that sirolimus reduces angiomyolipoma 
volume. However, the effect on bleeding from angiomyolipomas has not been evaluated. Further, 
the relative risk/benefit of treatment has not been compared to that of other established treatments 
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of angiomyolipoma (i.e. catheter embolisation, conservative surgery). The effect of mTOR 
inhibitors on pulmonary function is unclear and their use is associated with frequent adverse 
events. mTOR inhibitors may be a future therapeutic option in patients with LAM and further 
studies are required. 
Recommendations 
1.  Sirolimus should not be prescribed routinely outside clinical trials for pulmonary LAM. 
Patients with LAM should be encouraged to participate in clinical trials whenever 
possible.  (Grade) C (Quality) low (Benefit) small / weak (Consensus) very good 
2.  In renal angiomyolipoma mTOR inhibitors should not be used as first-line therapy. 
Sirolimus may be considered on an individual basis in patients with symptomatic 
angiomyolipoma or LAM-related masses not amenable to embolisation or conservative 
surgery in experienced centres. (Grade) C (Quality) low (Benefit) small / weak 
(Consensus) very good 
3.  In the current context of scientific uncertainty but possible treatment benefit; sirolimus 
may be considered on an individual basis in patients with rapid decline in lung function or 
symptoms, after careful evaluation of risk/benefit ratio in an experienced centre. When 
sirolimus is used, the effect of therapy should be carefully monitored for tolerance and 
effect on lung function at 3 monthly intervals. Sirolimus should be stopped once patients 
are listed for active lung transplantation. (Grade) C (Quality) low (Benefit) small / weak 
(Consensus) very good 
 
 
Complications and co-morbidities  
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Management of pneumothorax  
Pneumothorax is common in LAM. Forty percent of patients present with this complication and it 
occurs in two thirds of patients at some point in their disease. There is a recurrence rate of around 
75% of patients after first pneumothorax[10, 18]. The largest retrospective study has shown that 
on average patients have 3.5 pneumothoraces resulting in hospital admissions for 29 days[18]. In 
one study conservative treatment of pneumothorax by any of observation, aspiration, chest tube, 
or pleurodesis via chest tube, was associated with recurrence in two thirds of patients. Any 
surgical treatment including video assisted thorascopic (VATS) pleurodesis, pleural abrasion, 
pleurectomy, or open procedure was associated with a much lower recurrence rate[10]. In a larger 
series of 676 pneumothoraces in LAM, 17% were observed without intervention, 83% had either 
simple aspiration, chest tube or chest tube plus pleurodesis. Twenty-eight percent went on to have 
a surgical intervention, either mechanical pleurodesis, bullectomy or pleurectomy. In this study 
recurrence was again common after conservative treatment (66%) but was reduced by more than 
half by chemical (27%) or surgical (32%) pleurodesis (p<0.01). In both studies patients 
frequently needed more than one intervention for pneumothorax. 
Pleural surgery and lung transplantation 
Intra-pleural procedures causing a partially or completely fused pleural space and extensive 
pleural adhesions was previously considered a contraindication to lung transplantation. As 
experience with transplantation increased, previous intra-pleural procedures or thoracic surgery 
have become a relative, rather than absolute, contraindication to transplantation. However pleural 
surgery causing extensive adhesions increases the complexity of the operative dissection, pleural-
related peri-operative bleeding and operation time[18, 100, 147, 148]. In patients with LAM and 
previous pleural surgery, there is an increased likelihood of re-operation for haemorrhage and 
bleeding related death [100, 148, 149].  
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Conclusions 
Pneumothorax occurs in the majority of patients, results in significant hospital stays, and is 
frequently recurrent. Conservative treatments are associated with higher rates of recurrence than 
pleurodesis via chest tube or appropriate surgical interventions. Lung transplantation is feasible 
in patients with previous thoracic surgery or pleural procedures, although associated with 
increased technical difficulty in some cases and an increased risk or perioperative bleeding. 
Recommendations.  
1 Pneumothorax in LAM should ideally be managed jointly by a chest physician and 
thoracic surgeon. (Grade) C (Quality) low (Benefit) intermediate (Consensus) very 
good 
2 A chemical pleurodesis may be performed at first pneumothorax. Patients who do not 
respond to initial therapy including pleurodesis, should undergo an appropriate surgical 
procedure according to their clinical condition and local expertise. (Grade) C 
(Quality) low (Benefit) intermediate (Consensus) very good 
3 Patients with second pneumothorax should have an appropriate surgical procedure 
according to their clinical condition and local expertise. (Grade) C (Quality) low 
(Benefit) intermediate (Consensus) very good 
4 When transplantation is considered patients with a history of pleurodesis or 
pleurectomy should be referred to transplantation centres with experience of LAM to 
anticipate possible pleural complications. (Grade) C (Quality) low (Benefit) 
intermediate (Consensus) very good  
5 A history of pleurodesis or pleurectomy should not be considered a contraindication to 
lung transplantation in patients with LAM. However, patients should be informed of 
an increased risk of perioperative pleural bleeding (Grade) C (Quality) low (Benefit) 
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intermediate (Consensus) very good 
 
Management of chylothorax 
Chylothorax in LAM may have little impact on the patients symptoms, or cause marked 
dyspnoea. Various case reports and short series have reported on a range of procedures for the 
management of chylothorax occurring in the context of LAM. Some efficacy and clinical benefit 
have been reported anecdotally using various procedures, including thoracic duct ligation, 
thoracocentesis and talc pleurodesis[11, 20, 139, 150-155]. In the largest series to address this 
issue, chylothorax was seen in eight of 79 patients with LAM at a tertiary centre. Six had 
unilateral and two bilateral effusions. The size of the chylothorax varied and in some cases did 
not enlarge over time. Management ranged from thoracocentesis only, to thoracotomy with 
thoracic duct ligation and parietal pleurectomy. When needed, pleurodesis by instillation of 
sclerosing agents or parietal pleurectomy appeared to be effective in controlling 
chylothorax[152]. The use of pleuro-peritoneal shunts has also been reported in a small number 
of cases[155]. The use of fat free diet (with or without oral supplementation of medium-sized 
triglycerides) or fat free total parenteral nutrition has been used in anecdotal reports to minimize 
the volume of chyle formation[156]. In a similar manner to pneumothorax, pleural intervention 
for chylothorax may increase the risk of perioperative bleeding at lung transplantation. 
Conclusion  
Management of chylothorax in patients with LAM should be appropriate to the size and clinical 
impact of the effusion in individual patients. These interventions will also depend upon co-
morbid factors and local expertise. In a small number of cases pleurodesis with or without 
thoracic duct ligation has been effective in treating symptomatic chylothorax. For small, stable 
effusions observation or thoracocentesis may be sufficient.  
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Recommendations 
1. Patients with chylothorax may be placed on a fat free diet, with supplementation with 
mid-chain triglycerides. (Grade) expert opinion / C (Quality) expert opinion (Benefit) 
small / weak (Consensus) very good  
2. For treatment of symptomatic chylous pleural effusions the decision to intervene and 
technique used should be performed on an individual basis, based on clinical evaluation 
including amount of chyle collected, recurrence of chylothorax, respiratory condition of 
the patient and consideration of future lung transplantation. (Grade) expert opinion / B 
(Quality) expert opinion (Benefit) intermediate (Consensus) very good 
 
Treatment and follow up of angiomyolipoma 
As angiomyolipomas are benign, nephrectomy is not required for their removal. During the 
course of the disease angiomyolipomas may enlarge and/or further tumours may develop. TSC is 
associated with other renal lesions including simple cysts and polycystic kidney disease. Renal 
failure occurs requiring dialysis in 0.1-1% of patients with TSC[22, 38, 39, 42-46]. Therefore 
preservation of functioning renal tissue is important to avoid the need for renal replacement 
therapy: optimal treatment of angiomyolipoma should comprise a nephron sparing approach. 
Currently used approaches are selective embolisation and nephron sparing surgery. Embolisation 
of the renal arteries has been used in both prophylactic treatment of tumours to prevent bleeding 
and for emergency treatment of bleeding tumours. Small case series of embolisation for 
angiomyolipoma show the procedure is safe and reduces tumour volume by 24-56%. The 
procedure has been used in elective cases[157, 158] and to treat acute renal haemorrhage[159] 
including during pregnancy[121]. Renal function is generally preserved and although re-bleeding 
may occur it is infrequent[108, 158-161]. In one study of 30 angiomyolipomas treated by 
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embolisation there was a 30% incidence of recurrent symptoms or increase in size (>2cm) 
requiring further embolisation over a mean follow up of 51 months. Recurrence was more 
common in patients with TSC[162]. In another series of 21 patients followed for up to 21 years 
tumour recurrence was infrequent[36]. Complications of embolisation include failure to occlude 
the blood supply and tumour liquefaction occasionally requiring drainage. Additionally, post-
embolisation syndrome characterised by flank pain and fever occurs in up to 80% of those treated 
and may be reduced by corticosteroid treatment[163]. 
Nephron sparing surgery for angiomyolipoma in both elective situations and when actively 
bleeding has been described in a number of case reports and two case series. In one series 
nephron sparing surgery of 28 angiomyolipomas was performed either to prevent bleeding in 
large tumours (16%), to treat bleeding tumours (20%), or for diagnostic uncertainty (64%). After 
a mean follow up of 55 months there had been no local recurrences and no change from pre-
operative serum creatinine levels although two patients developed ureteric fistula[164]. In a 
second retrospective study 23 patients with larger, predominantly symptomatic tumours 
underwent surgery without significant complications[165]. 
Conclusions 
Although clinical experience is based entirely on data from case series, both embolisation and 
nephron sparing surgery have been performed safely to reduce tumour volume in 
angiomyolipoma without compromising renal function. However there is no agreement as to 
when renal angiomyolipoma may need intervention other than during, or after, an episode of 
haemorrhage. Embolisation has the advantage of being less invasive and not requiring general 
anaesthesia but it may need to be repeated and can result in post embolisation syndrome. 
Embolisation can also be performed for active bleeding including during pregnancy[166]. 
Although, for these reasons, embolisation may be favoured over surgery in patients with bleeding 
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angiomyolipoma, there are no trials comparing the two strategies. The decision as to which 
option is taken may depend upon technical factors associated with the tumour, whether the 
patient can tolerate general anaesthesia and local expertise. In elective cases where bleeding is 
not present, nephron sparing surgery may be preferred when a malignant lesion is suspected after 
imaging. Surgery with intra-operative frozen section biopsy may be considered with the option to 
perform conservative or radical surgery as appropriate; however the risk of a false diagnosis of 
carcinoma must be borne in mind[167]. Where possible, these decisions are best made electively 
after screening for angiomyolipoma or in response to symptoms rather than in the setting of an 
acute haemorrhage. Early detection of angiomyolipoma is therefore important in patients with 
LAM. 
Recommendations 
1. Patients should be advised to seek urgent medical attention in the presence of symptoms 
of bleeding angiomyolipoma. (Grade) B (Quality) low (Benefit) substantial 
(Consensus) very good 
2. Embolisation should be first-line treatment for bleeding angiomyolipoma. Nephron 
sparing surgery is also acceptable dependent upon local expertise. (Grade) expert 
opinion / B (Quality) expert opinion (Benefit) substantial (Consensus) very good 
3. Embolisation should be performed as first line therapy of angiomyolipoma in elective 
cases, with nephron sparing surgery indicated where a malignant lesion cannot be 
excluded. Technical factors associated with the tumour blood supply and local expertise 
should also be taken into account. (Grade) C (Quality) low (Benefit) intermediate 
(Consensus) very good 
When is treatment of angiomyolipoma indicated in asymptomatic patients?  
The natural history of angiomyolipoma in LAM and TSC has mainly been reported in two series 
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comprising a total of 58 patients[107, 168]. Indicators of the risk of bleeding are tumour size[36, 
107] and the presence of aneurysms[168]. Aneurysm formation appears to be related to tumour 
size and larger aneurysms confer a higher probability of rupture. Aneurysms are not well 
visualised by CT and renal angiography is required although this is not routinely performed. 
Tumour size was larger than 4 cm and aneurysms were 5 mm or larger in all hemorrhagic 
lesions[168]. Patients with TSC and angiomyolipomas had a higher incidence of bilateral renal 
involvement, larger tumours that were more likely to grow and more frequently required 
surgery[107]. In addition, angiomyolipomas almost exclusively composed of fat are less likely to 
bleed, whereas those with rapid growth are more likely to bleed. Patients with larger tumours 
contemplating pregnancy or undergoing lung transplantation may also have increased bleeding 
risk. 
Conclusions  
The risk of bleeding of angiomyolipoma is linked to tumour size and is clinically appreciable in 
tumours 4 cm in diameter or larger and where aneurysms 5 mm or larger are present.  
Recommendations  
1  Asymptomatic renal angiomyolipoma under 4 cm should not be treated, but should be 
followed by yearly ultrasound unless symptoms occur. Where ultrasound measurements 
are unreliable due to technical factors, CT or MRI should be performed. (Grade) B 
(Quality) low (Benefit) substantial (Consensus) very good 
2  Renal angiomyolipomas greater than 4 cm or with renal aneurysms greater than 5 mm 
in diameter are at an increased risk of bleeding, and should be followed by ultrasound 
imaging twice yearly to evaluate growth. Treatment by embolisation or nephron sparing 
surgery should be considered. (Grade) expert opinion / A (Quality) expert opinion 
(Benefit) substantial (Consensus) very good 
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Lung transplantation for LAM 
LAM accounts for 1.1% of lung transplant recipients in the International Registry of Heart and 
Lung transplantation[169]. Overall survival varies according to the cohort described, although 
there have been no significant differences in early or late mortality, length of intensive care unit 
or hospital stay or overall survival in LAM patients compared to patients transplanted for other 
indications[100, 148, 170, 171]. In a recent survey the actuarial survival of lung transplantation 
for LAM was 86% at 1 year, 76% at 3 years, and 65% at 5-years[171]. 
 
Referral criteria for lung transplantation 
Due to the small number of patients treated, coupled with the variable rates of fall in lung 
function in LAM mean firm recommendations are difficult to make. As discussed, factors 
predicting the rate of decline have not been studied prospectively[3, 25, 26, 57, 100, 149]. As a 
result transplant decisions are generally made after serial observation of clinical and 
physiological parameters. In a recent survey of patients undergoing transplantation for LAM, 
most had severe airway obstruction and were transplanted with a mean FEV1 of around 25% and 
DLCO of 27% predicted. About 15% had a combined restrictive-obstructive pattern. In the 
published series of transplanted patients with LAM, differences in mortality and morbidity 
between younger and older women were not examined and there is no evidence that the age at 
transplantation affects the postoperative outcome. The oldest patient reported was 65 years[171]. 
The upper age limit is dependent on the transplantation policy of the country. 
Conclusions 
Until better prognostic indicators are found to predict the clinical course of LAM, patients should 
be considered for lung transplantation when they reach NYHA functional class III or IV with 
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severe impairment in lung function and exercise capacity (VO2 max <50% predicted, 
hypoxaemia at rest). The upper age limit for transplantation in patients with LAM will depend 
upon the patients’ wishes, co-morbidities and local access to transplantation. However 
transplantation above 65 years may only exceptionally be considered. 
Recommendation 
1. Patients should be considered for lung transplantation when they reach NYHA functional 
class III or IV with hypoxemia at rest, severe impairment in lung function and exercise 
capacity (VO2 max<50% predicted). (Grade) A (Quality) fair (Benefit) substantial 
(Consensus) very good 
 
Which type of transplantation is indicated in LAM ? 
Single, bilateral lung and more rarely, heart-lung transplantation have been performed 
successfully for LAM. In the International Society of Heart and Lung Transplantation registry 
report (2006), 54 single and 88 bilateral lung transplants had been performed for LAM with the 
type of procedure depending on the surgical team and the country[171, 172]. The type of 
transplant did not affect survival in the largest patient cohort[171]. Bilateral lung transplant has 
been favoured over single lung transplant for LAM due to LAM-related complications in the 
native lung after single lung transplant including recurrent pneumothorax, over inflation leading 
to compression of the graft[100, 171, 173] and the theoretical risk of recurrence of host origin to 
spread from the remaining native lung[148, 171, 173]. In addition, lung function was better in 
double lung transplant recipients[100, 111],[173] although no differences were found in subjective 
measures of function between single and double lung recipients[111]. Living donor lobar lung 
transplantation has been applied to patients with various end-stage lung diseases, with only a 
small number of case reports in LAM[174].  
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Conclusions 
No significant difference in survival with single and bilateral lung transplant has been seen, 
although bilateral lung transplant is associated with better post transplant lung function and 
probably a reduction in LAM related complications. 
Recommendations 
1. The choice of single lung transplant or bilateral lung transplant in LAM should be 
determined by surgical technical factors and organ availability. (Grade) B (Quality) fair 
(Benefit) intermediate (Consensus) very good 
 
Special considerations related to lung transplantation for patients with TSC 
Patients with TSC have received successful lung transplantation for severe LAM. From two 
recent series nearly 10% of the transplanted patients had TSC-LAM[173, 175]. Although no TSC 
specific problems have been identified, no systematic studies examining the outcome of 
transplantation in this group of patients have been performed. Clearly patients with TSC-LAM 
are likely to have more co-morbidities than those with sporadic LAM. Almost all patients with 
TSC-LAM have co-existent angiomyolipoma, which may be bilateral, and many have epilepsy or 
learning difficulties. The impact of these processes and their treatment require careful pre-
transplant evaluation. 
Recommendations.  
1. Patients with TSC in the context of LAM should not be precluded from lung 
transplantation  by TSC alone. Some patients may have TSC related medical or cognitive 
problems which preclude transplantation. (Grade) B (Quality) low (Benefit) substantial 
(Consensus) very good 
2. TSC-LAM patients should have careful multi-disciplinary assessment when being 
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evaluated for lung transplantation. (Grade) B (Quality) low (Benefit) substantial 
(Consensus) very good 
 
Does the presence of an angiomyolipoma affect lung transplant suitability ? 
Angiomyolipoma in patients with sporadic LAM are generally small, have a low rate of growth 
and do not affect renal function. In those with TSC-LAM, angiomyolipoma are almost always 
present, and are more likely to be large, bilateral and multiple[40]. Detection of renal 
angiomyolipoma in LAM is important preoperatively, as the risk of bleeding associated with a 
large angiomyolipoma is well established. In two recent series, renal angiomyolipoma were 
detected in 35-38% of LAM patients during pre-transplant assessment[149, 173]. In one series 
4/13 patients had complications related to renal angiomyolipoma, including retroperitoneal 
haemorrhage (requiring nephrectomy in 2), renal colic and renal failure. There was no difference 
in the incidence of post-transplant renal insufficiency in those with angiomyolipoma over those 
transplanted without angiomyolipoma. The major risk factor for renal impairment in all series 
was the use of calcineurin inhibitors[149, 173].  
Recommendation 
1. Angiomyolipoma may not be a contra-indication to lung transplantation but may affect 
transplant suitability, surgery and postoperative follow up. (Grade) B (Quality) low 
(Benefit) substantial (Consensus) very good 
2. The presence of renal angiomyolipoma should be sought in the preoperative assessment, 
and those at risk of bleeding should be treated prior to transplantation. (Grade) B 
(Quality) low (Benefit) substantial (Consensus) very good 
Should the possibility of recurrent LAM in the graft be investigated post transplant? 
LAM can recur in the allograft of both single and bilateral lung transplant. However, this is a rare 
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event and generally asymptomatic. Recurrent LAM has been identified at post mortem 
examination or in biopsies performed for other purposes. Recurrent LAM does not seem to affect 
survival post transplantation[100, 148, 171, 176-178].  
Recommendation 
1. Routine investigation for recurrent LAM post transplantation with biopsy should not be 
performed. (Grade) D (Quality) low (Benefit) negative (Consensus) very good 
 
Post transplant immunosuppression regimen for LAM 
There have been no studies of post transplant regimens for patients with LAM. The same 
immunosuppressive regimen has been given as for other indications[148, 170, 173, 179]. In one 
study 50% of patients received induction therapy followed by maintenance immunosuppression 
consisting of conventional triple therapy (calcineurin inhibitor / metabolite antagonist / 
prednisolone). None received an mTOR inhibitor. The morbidity resulting from long-term 
immunosuppression was similar for LAM and non-LAM recipients[148].  
Recommendation 
1. Post-transplant regimen for patients with LAM should be the same as for other indications.  
(Grade) C (Quality) low (Benefit) intermediate (Consensus) very good 
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